People: Opexa Therapeutics, Inc. (OPXA.O)

OPXA.O on Consolidated Issue listed on NASDAQ Capital Market

1.95USD
9 Feb 2010
Price Change (% chg)

$0.02 (+1.04%)
Prev Close
$1.95
Open
--
Day's High
$2.06
Day's Low
$1.85
Volume
82,564
Avg. Vol
195,277
52-wk High
$6.93
52-wk Low
$0.25

view people for:

Summary

Name Age Since Current Position
Warma, Neil 46 2009 President, Chief Executive Officer, Acting Chief Financial Officer
Rill, Donna 55 2009 Senior Vice President - Operations
Thompson, Jaye 2009 Senior Vice President - Clinical Development and Regulatory Affairs
McWilliams, David 65 2008 Director
Seaman, Scott 53 2006 Director
Richman, Michael 48 2006 Director
Hung, David 51 2006 Director
Jorden, David 46 2008 Director
» Insider Trading

Biographies

Name Description
Warma, Neil Mr. Neil K. Warma has served as President and Chief Executive Officer of Opexa Therapeutics, Inc. since June 2008 and as Acting Chief Financial Officer since March 2009. From July 2004 to September 2007, Mr. Warma served as president and chief executive officer of Viron Therapeutics Inc., a privately-held clinical stage biopharmaceutical company. From 2000 to 2003 Mr. Warma was co-founder and president of MedExact USA, Inc., an Internet company providing clinical information and services to physicians and pharmaceutical companies. From 1992 to 2000 Mr. Warma held senior positions of increasing responsibility at Novartis Pharmaceuticals (previously Ciba-Geigy Ltd.) at its corporate headquarters in Basel, Switzerland. While at Novartis, Mr. Warma served as the Head of International Pharma Policy & Advocacy and in senior management within global marketing where he worked on the international launch of a gastrointestinal product. Mr. Warma obtained an honors degree specializing in Neuroscience from the University of Toronto and an International M.B.A. from the Schulich School of Management at York University in Toronto.
Rill, Donna Ms. Donna R. Rill served as Senior Vice President of Operations of Opexa Therapeutics, Inc. since January 2009. From November 2004 until January 2009 she served as Vice President of Operations. From April 2003 to November 2004, she was the director of quality systems and process development at Opexa Pharmaceuticals, Inc. From November 1997 to April 2003 she was the director of translational research for the Center for Cell & Gene Therapy at Baylor College of Medicine. Ms. Rill has worked to design and qualify GMP Cell & Gene Therapy Laboratories, GMP Vector Production facilities, and Translational Research Labs at St. Jude Children’s Research Hospital, Texas Children’s Hospital, and Baylor College of Medicine. Ms. Rill received her B.S. in Medical Technology from the University of Tennessee, Memphis.
Thompson, Jaye Dr. Jaye Thompson has been appointed as Senior Vice President of Clinical Development and Regulatory Affairs of Opexa Therapeutics, Inc. Dr. Thompson has significant experience in clinical development having been the president and founder of SYNERGOS, Inc., a full service contract research organization which she managed and successfully grew until its acquisition by inVentiv Health (NASDAQ:VTIV) in 2006. She has advised a number of life science companies on strategic and regulatory planning as well as clinical product development. She has directed and managed statistical analysis, data management, report writing and the conduct of clinical trials for a wide variety of indications including MS. Dr. Thompson has been actively involved in over 200 clinical trials for drugs and has been associated with numerous FDA regulatory submissions. Dr. Thompson has a Bachelor's degree in Applied Mathematics and a Ph.D. in Biostatistics.
McWilliams, David Mr. David B. McWilliams has served as Director of Opexa Therapeutics, Inc. since August 2004. From August 2004 to June 2008 Mr. McWilliams also served as President and Chief Executive Officer of Opexa. From December 2003 until August 2004, Mr. McWilliams was a private investor. From June 2003 to December 2003, Mr. McWilliams served as president and chief executive officer of Bacterial Barcodes, Inc., a molecular diagnostics company. Mr. McWilliams currently serves as a director of Novelos Therapeutics, Inc., and on the boards of ApoCell Biosciences and the Houston Technology Center. Mr. McWilliams received an MBA in finance from the University of Chicago and a B.A. in chemistry, Phi Beta Kappa, from Washington and Jefferson College.
Seaman, Scott Mr. Scott B. Seaman has served as a Director of Opexa Therapeutics, Inc. since April 2006. Mr. Seaman has served for over five years as the executive director and treasurer of the Albert and Margaret Alkek Foundation of Houston, Texas, a private foundation primarily supporting institutions in the Texas Medical Center in Houston, Texas. Since January 1996 to present, Mr. Seaman has served as the chief financial officer of Chaswil Ltd., an investment management company. Since September 1986, Mr. Seaman has served as secretary and treasurer of M & A Properties Inc., a ranching and real estate concern. Since January 2003, Mr. Seaman has served as chairman and, since July 2004, president of ICT Management Inc., the general partner of Impact Composite Technology Ltd., a composite industry supplier. Mr. Seaman serves on the board of GeneExcel, Inc., a privately held biotechnology company. Since May 2004, Mr. Seaman has served as a Member of the Investment Committee of Global Hedged Equity Fund LP, a hedge fund. Mr. Seaman received a bachelor’s degree in business administration from Bowling Green State University and is a certified public accountant.
Richman, Michael Mr. Michael S. Richman has served as a Director of Opexa Therapeutics, Inc. since June 2006. Mr. Richman has served as president and chief executive officer of Amplimmune, Inc. since July 2008. Mr. Richman served as president and chief operating officer of Amplimmune, Inc. from May 2007 to July 2008. From April 2002 to May 2007, Mr. Richman served as executive vice president and chief operating officer of MacroGenics, Inc. Mr. Richman joined MacroGenics, Inc in 2002 with approximately twenty years experience in corporate business development within the biotechnology industry. Mr. Richman serves on the board of Cougar Biotechnology, a public drug development company. Mr. Richman obtained his B.S. in Genetics/Molecular Biology at the University of California at Davis and his MSBA in International Business at San Francisco State University.
Hung, David Dr. David Hung, M.D. has served as a Director of Opexa Therapeutics, Inc. since May 2006. Dr. Hung has served as the president, chief executive officer and as a director of Medivation, Inc. since December 2004. Dr. Hung also has served as the president and chief executive officer, and member of the board of directors, of Medivation, Inc.’s subsidiary, Medivation Neurology, Inc. since its inception in September 2003. From 1998 until 2001, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer (1998-1999), and as president and chief executive officer (1999-2001). From December 2001 to January 2003, Dr. Hung served as a consultant to Cytyc Health Corporation. Dr. Hung received his M.D. from the University of California at San Francisco, and his A.B. in biology and organic chemistry from Harvard College.
Jorden, David Mr. David Emerson Jorden has served as a Director of Opexa Therapeutics, Inc. since August 2008. Mr. Jorden has served as executive board member for Cytomedix, Inc. since October 2008. Mr. Jorden previously served as vice president with Morgan Stanley in its Wealth Management group where he is responsible for equity portfolio management for high net worth individuals since 2003. Prior to Morgan Stanley, Mr. Jorden served as vice president and chief financial officer of Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications from March 2000 to September 2002. Mr. Jorden was a principal with Fayez Sarofim & Co. prior to joining Genometrix. Mr. Jorden earned a MBA from Kellogg School of Management at Northwestern University in 1989 and a BBA from the University of Texas/Austin in 1984. He currently serves as a director of Cytomedix, Inc. and PLx Pharma, Inc. Mr. Jorden is a Chartered Financial Analyst and Certified Public Accountant.

Basic Compensation

Name Fiscal Year Total
Warma, Neil 330,456
Rill, Donna 252,288
Thompson, Jaye --
McWilliams, David 849,018
Seaman, Scott --
Richman, Michael --
Hung, David --
Jorden, David --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Warma, Neil 0 0
Rill, Donna 0 0
Thompson, Jaye 0 0
McWilliams, David 420,000 0
Seaman, Scott 0 0
Richman, Michael 0 0
Hung, David 0 0
Jorden, David 0 0

Insider Trading

Name Shares Traded Price
JORDEN DAVID EMERSON 25,000 $1.95
JORDEN DAVID EMERSON 25,000 $2.05
JORDEN DAVID EMERSON 4,500 $2.20
JORDEN DAVID EMERSON 38,000 $2.00
HUNG DAVID T 20,200 $4.18
HUNG DAVID T 6,800 $1.53
HUNG DAVID T 20,000 $1.43
HUNG DAVID T 10,000 $1.60
HUNG DAVID T 5 $1.60
ROTH MICHAEL A 500 $0.25
ROTH MICHAEL A 250,000 $0.26
ROTH MICHAEL A 195,000 $0.21
ROTH MICHAEL A 184,376 $0.21
AUSTIN W MARXE ET AL 25,000 $2.39
AUSTIN W MARXE ET AL 1,000 $2.45
SEAMAN SCOTT B 15,105 $1.66
HUNG DAVID T 15,105 $1.66
WARMA NEIL K 3,021 $1.66
HUNG DAVID T 31,900 $1.09
BAILEY GREGORY H 31,000 $1.09
AUSTIN W MARXE ET AL 5,499 $1.30
AUSTIN W MARXE ET AL 100 $1.40
AUSTIN W MARXE ET AL 399 $1.75
AUSTIN W MARXE ET AL 114 $1.75
SEAMAN SCOTT B 10,000 $2.00
» Full list on Insider Trading
view people for: